Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03OFF
|
||||
| Former ID |
DAP000272
|
||||
| Drug Name |
Pioglitazone
|
||||
| Synonyms |
Actos; Actost; Duetact; Glustin; Pioglitazona; Pioglitazonum; Zactos; AD 4833; U 72107; U 72107A; AD-4833; Actos (TN); Glustin (TN); HS-0047; Pioglitazona [INN-Spanish]; Pioglitazone (INN); Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Pioglitazonum [INN-Latin]; U-72107; U72,107A; Zactos (TN); (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-(9CI); 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Hypoglycemic Agents
|
||||
| Company |
Takeda Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H20N2O3S
|
||||
| InChI |
InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
|
||||
| InChIKey |
HYAFETHFCAUJAY-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 111025-46-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9877, 841973, 5514443, 7980327, 8152965, 10852019, 11364517, 11367079, 11369641, 11372042, 11374757, 11377803, 11485633, 11489495, 11490817, 11492944, 11495437, 14828061, 22395182, 26756476, 29223911, 46507136, 47359443, 47805056, 48403962, 49836649, 50052255, 50111371, 50830677, 53790062, 56311254, 56312043, 56313970, 56313978, 56314560, 57288465, 57288698, 57288809, 57322474, 81040922, 85789264, 92308830, 92712064, 96025064, 103181943, 103853946, 104307547, 117695425, 118855323, 124892398
|
||||
| ChEBI ID |
ChEBI:8228
|
||||
| SuperDrug ATC ID |
A10BG03
|
||||
| SuperDrug CAS ID |
cas=111025468
|
||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator activated receptor gamma | Target Info | Agonist | [535579] | |
| PANTHER Pathway | CCKR signaling map ST | ||||
| WikiPathways | Wnt Signaling Pathway Netpath | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Differentiation of white and brown adipocyte | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Adipogenesis | |||||
| SREBP signalling | |||||
| Nuclear Receptors | |||||
| References | |||||
| Ref 537022 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | ||||
| Ref 539756 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2694). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.